Analysis of samples from melanoma patients undergoing various immunotherapeutic treatments, including cancer vaccines and immune checkpoint blockade with CTLA-4 and PD-1 antagonists, revealed that tumors responsive to immunotherapy tend to be infiltrated with T cells, which is described as “T cell-inflamed” tumor microenvironment (22, 82–84). The gene discussed is CTLA4; the disease is neoplasm.